IFN-OAd

IFN-OAd is an experimental oncolytic adenovirus engineered to express interferon (IFN), specifically interferon-alpha, under the control of a tumor-specific promoter such as survivin. Developed primarily by researchers at Kagoshima University, this therapeutic approach aims to overcome the systemic toxicity and poor delivery associated with recombinant IFN therapy by ensuring localized, high-concentration IFN production within the tumor microenvironment. In preclinical studies for pancreatic ductal adenocarcinoma (PDAC), IFN-OAd has demonstrated synergistic antitumor activity when combined with radiation and standard-of-care chemotherapies like gemcitabine and nab-paclitaxel. The virus works through dual mechanisms: direct oncolysis (viral-mediated cell death) and the induction of potent antitumor immunity, characterized by increased recruitment of tumor-infiltrating lymphocytes (TILs).

Other names

oncolytic adenovirus-expressing IFNIFN-expressing oncolytic adenovirusAd-Surv-IFNAd-IFN-alpha